These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25593234)

  • 1. Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests.
    van Weely SF; Dekker J; Steultjens MP; van Denderen JC; Nurmohamed MT; Dijkmans BA; van der Horst-Bruinsma IE
    J Rheumatol; 2015 Apr; 42(4):623-9. PubMed ID: 25593234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function.
    van Weely SF; van Denderen JC; Steultjens MP; Nurmohamed MT; Dijkmans BA; Dekker J; van der Horst-Bruinsma IE
    Rheumatology (Oxford); 2013 Oct; 52(10):1884-9. PubMed ID: 23864170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
    Nossent JC; Sagen-Johnsen S; Bakland G
    J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of incentive spirometer exercise on pulmonary functions of patients with ankylosing spondylitis stabilized by tumor necrosis factor inhibitor therapy.
    So MW; Heo HM; Koo BS; Kim YG; Lee CK; Yoo B
    J Rheumatol; 2012 Sep; 39(9):1854-8. PubMed ID: 22859343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of performance measures of physical function based on the BASFI, in ankylosing spondylitis.
    van Weely SF; van Denderen CJ; van der Horst-Bruinsma IE; Nurmohamed MT; Dijkmans BA; Dekker J; Steultjens MP
    Rheumatology (Oxford); 2009 Oct; 48(10):1254-60. PubMed ID: 19638455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial.
    Masiero S; Bonaldo L; Pigatto M; Lo Nigro A; Ramonda R; Punzi L
    J Rheumatol; 2011 Jul; 38(7):1335-42. PubMed ID: 21459942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
    Gulyas K; Bodnar N; Nagy Z; Szamosi S; Horvath A; Vancsa A; Vegh E; Szabo Z; Szucs G; Szekanecz Z; Szanto S
    Eur J Health Econ; 2014 May; 15 Suppl 1():S93-100. PubMed ID: 24832840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
    Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
    Wanders AJ; Gorman JD; Davis JC; Landewe RB; van der Heijde DM
    Arthritis Rheum; 2004 Feb; 51(1):1-8. PubMed ID: 14872448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
    Prince DS; McGuigan LE; McGirr EE
    Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
    Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
    Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
    Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
    Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.